Pasithea Therapeutics KTTA
NASDAQ KTTA
$0.49 +0.00 (+0.61%)
At close: Sep 30, 2026 · 4:00 PM EDT

Pasithea Therapeutics (KTTA) EBITDA Margin (2022)

Updated

Pasithea Therapeutics' EBITDA Margin came in at -1677.80% for Q4 2022, up 78.33 percentage points from the prior quarter.

Analysis

Pasithea Therapeutics (KTTA) EBITDA Margin (2022) Analysis & Trends

For FY2022, Pasithea Therapeutics' EBITDA Margin was -2586.12%, up 27330.45 percentage points from FY2021.

  • Going back by year, EBITDA Margin was -29916.57% in FY2021.
  • Business Quant data shows KTTA's EBITDA Margin at -1756.14% (Q3 2022), -19150.08% (Q2 2022) and -17568.63% (Q1 2022) in the three quarters before Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 35.95%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 49.01%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 6.02%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 33.11%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 46.01%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 39.10%
10 Pasithea Therapeutics 16.37 Mn 16.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -1,677.80%
Sep 30, 2022 -1,756.14%
Jun 30, 2022 -19,150.08%
Mar 31, 2022 -17,568.63%
API Access

Pasithea Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KTTA&period=max&api_key=YOUR_API_KEY